StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
June 10, 2024 8:58 AM
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $310.00 price target on Moderna (NASDAQ: MRNA).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Midday movers: Southwest Airlines, CrowdStrike, KKR rise; AMD falls
June 10, 2024 8:09 AM
Morgan Stanley Reiterates Equalweight Rating on Moderna (MRNA)
June 10, 2024 6:52 AM
Jefferies on Moderna (MRNA): 'Phase III Flu/Covid Combo looks good - could be on market in 2025'
June 10, 2024 6:52 AM
Moderna (MRNA) Reports Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
June 10, 2024 5:31 AM
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
June 10, 2024 5:31 AM
Form 4 Moderna, Inc. For: Jun 05 Filed by: AFEYAN NOUBAR
June 7, 2024 7:00 PM
Moderna (MRNA) Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
June 7, 2024 10:31 AM
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
June 7, 2024 10:31 AM
Moderna (MRNA) option implied volatility amid price movement
June 7, 2024 5:16 AM
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)
June 6, 2024 7:51 AM
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
June 6, 2024 7:26 AM
